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Abstract 
A significant and often neglected obstacle in new product development is the testing and 
approval process in the late stages of development. The testing process has primarily been 
observed as an in-house decision process, however, in many industries products undergo 
extensive testing before market launch where external stakeholders play a key role. Users are 
often integrated in testing of new product candidates, and supply valuable knowledge to 
developers by testing the new product in natural business settings. As especially high-tech 
products are closely linked to related services and usage patterns, utilization of users input to 
not only product functionality, but also the related services and usage patterns are relevant.  
This study contributes to the literature on these crucial phases of late stage product 
development, by exploring developers’ utilization of the knowledge and experiences 
generated by users in product testing. Further, the important user network in high-tech 
product testing may likely be globally dispersed, and the mean of communicating between 
user and producer in the testing process are therefore tested. 
A dataset of 395 site-representatives are applied to study the knowledge generated and 
shared by medical sites and Pharmaceutical producers in late stage product development.  
The results show, that information regarding usage patterns and product related services are 
more difficult to transfer between user and developer, than issues directly related to the 
product. Further, with a dispersed user network a positive effect is observed on the mean to 
communicate directly as issues occur. The effect of virtual communication is therefore 
stronger than traditional face-to-face interaction patterns.  
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Introduction 
The down-stream development processes, such as prototype development, -testing and 
market introduction, are important measures in NPD and the later market performance. It is 
in these late stages new technologies are developed into products, and are subject to critical 
tests before market launch (Cooper 2001; Barczak ét al. 2009). As firms’ technological 
capabilities expand and more unique products are developed, the testing phases play a more 
central role in NPD processes (Dolan and Matthews, 1993). This is further emphasized, as 
many technologies are often highly connected to related services relevant for the new product 
(Tukker and Tischner 2006; Mont 2002; Morelli 2006). As many products are closely linked 
to related services, users role becomes even more prevalent in the critical testing processes. 
Further, usability patterns are increasingly important, as usability measures such as users 
convenience and practical application of a product can have huge influence on market 
performance besides the products concrete effect (Bevan 1995, MaGuire 2001, Alonso-Rios 
ét al. 2010). The testing phases in late stage development can thereby supply user input to 
product functionality, but also product related services and usability patterns of the new 
product.  
This is especially the case in high-tech industries, as users integrated in the development 
process are often highly skilled and knowledgeable. High-tech users will often have in-depth 
knowledge about the market, and therefore expertise concerning the product area, usage 
patterns and related service required for product application. This could be knowledge related 
to issues such as the workforce required in managing the product, access to the new product 
and attitude to product profile in the market. By integrating the new product in daily business 
processes, users can apply the product and supply firms with valuable knowledge. This 
knowledge could then result in prototype adjustments, spin-off products, new market 
applications or segmentation differentiation.  
There is a gap in extant literature in exploring the organization and optimization of the crucial 
testing phases, and here the industry’s utilization of user input in these late stages of 
development. This paper seeks to meet this gap by exploring the information processing 
dynamics between users and producers in the testing processes before market launch. 
Producers have a unique opportunity to tap into knowledge generated by competent users 
with experiences in the market and product through their participation in product testing. We 
therefore explore how difficult product related aspects are generated by the users and then 
shared with the producer in relation to service and usability related issues.  
As users are most likely located in multiple global locations, the effect of communication 
mean should also be considered in relation to the difficulty of generating and sharing 
knowledge between user and product during testing phases. This especially apply in high-
tech industry product testing, where industry have an interest in integrating professional users 
with expertise in the product area in the testing process. These users may therefore be 
dispersed, both from each other and from firm representatives, and the way of interaction 
such as face-to-face meetings, virtual or written means is considered in this study.  
To investigate the difficulty of generating and sharing knowledge between user and producer 
by topic area focus is drawn to a high technology driven market – drug development. The 
Pharmaceutical industry is an interesting case of down-stream partnerships, as future users 
are directly integrated in the processes of product development. New product prospects 
undergo extensive testing phases (clinical trials), which are conducted by medical sites such 
as private clinics, health centers, hospitals, and academic medical centers. The physician’s 
expertise within the therapeutic area, as well as their link to patients, is a valuable asset for 
the Pharmaceutical industry (Getz and Zuckerman 2010). The patients can be defined as the 
end-user in relation to new drugs, however, as the medical sites are those whom prescribe 
drugs and therefore make the main decisions on product type and usage, these are defined as 
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the user in this analysis. We test our theoretical derived hypotheses on a sample of 395 
responses from medical sites. The difficulty of generating and sharing knowledge between 
user and producer during testing phases is analyzed by applying a Rasch Scale model (Item 
Response Theory).  
 
The paper proceeds as follows. First the conceptual model is presented, which leads to the 
hypotheses. Second, the case and data collection is presented, as well as the method applied 
in the analysis. Third, the results of the analysis are presented and hereafter discussed, and 
lastly conclusions and managerial implications as wells as limitations and further research. 
 
 
Conceptual model and hypotheses´ 
User input in new product testing 
Product testing is a central element in late stages of development. Especially in high-tech 
industries product testing is a key measure, as the often time-consuming research and early 
development phases are now being tested for the market. In NPD studies the primary goal of 
the testing phases is defined as product functionality, and market intelligence measures 
before launch (Cooper 2001; Barczak ét al. 2009). Here the users play a central role, as they 
are integrated in these late stages of development to participate in the product testing 
processes. Users are applied in the prototype testing in the late stages of development often 
conducted for marketing purposes (Thomke and von Hippel, 2002; Cooper 2001), as well as 
creating early adopters of the product and influence opinion leaders (van Eck, Jager and 
Leeflang, 2011; Chiesa and Frattini, 2011). 
However, the testing processes can supply industrial development processes with more than 
merely prototype testing for functionality, and marketing measures (Dolan and Mathews 
1993). As new products are being applied in natural business settings, users can test new 
products, but also generate information about product related services (Tukker and Tischner 
2006; Mont 2002; Morelli 2006), and usability patterns (Bevan 1995, MaGuire 2001, Alonso-
Rios ét al. 2010). This especially applies in relation to more complex products, where the 
integration of a product in daily business processes may supply information, which is 
difficult to duplicate in in-house alpha testing programs (Dolan and Mathews 1993).  
In product testing processes users can thereby supply information about product functionality 
and then related services (Tukker and Tischner 2006; Mont 2002; Morelli 2006). In industries 
such as car manufacturing, users can supply information about the functionality of the car, 
but applying the car in a natural setting can also generate information about services related 
to the product, such as maintenance issues (Williams 2006).  
Besides product functionality and related services, also usability patterns are relevant in the 
testing phases. Usability is often mentioned in relation to the increasing focus on design 
measures in new product development (Bevan 1995, MaGuire 2001). Testing for usability 
measures requires application of the product in use, and usability is therefore often referred to 
context-of-use measures (Bevan 1995, MaGuire 2001, Alonso-Rios ét al. 2010). Context-of-
use by applying new products to users natural business settings can thereby supply valuable 
information about usability of the new product beyond basic functionality issues. Usability 
issues are relevant in various industries such as medical devices where eg. ostomy care 
products, are not only tested for product effect, but also patient convenience in the use. Or IT 
products such as recent developments of tablets where not only product functionality, but 
also usability measures can be tested in use, such as the user interface, and product size, 
dimensions etc.. 
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Figure 1: Late stage product development opportunities 
 
The testing phases of new product development can supply producers with valuable product-
in-use information concerning product functionality, product related services and usability 
patterns. The users ability to share their information is therefore a valuable asset in product 
testing optimization. Differentiating users knowledge sharing ability in product testing 
concerning product functionality, related services and usability patterns can thereby support 
further understanding of the utilization of a key stakeholder in product testing, which leads to 
the following hypothesis:  
 
Hypothesis 1: Direct product related aspects are easier generated and shared than product 
related service-, and usability related issues. 
 
 
Communication mean and knowledge sharing ability 
In order to utilize the information gained by users during product testing channels of 
communication needs to be established between user and producer. Previous studies on 
information processing have pointed to the balance between co-location of partners vs. cross-
distance communication means such as web-based solutions (Song ét al. 2005, Bathelt and 
Turi, 2011; Song ét al. 2007). A characteristic in the collaboration between producers and 
their network of professional users is that these actors are not located at the same place as the 
in-house staff. Users in general and especially when qualified by their professional profile are 
likely to be located in many global locations. When questioning the knowledge transfer 
process in the crucial testing processes the dispersed relationship should be considered, and 
therefore the means of communicating between user and producer.   
Communication mean is defined in three formats: 1) Communication where actors are at the 
same location at the same time, which implies a traditional face-to-face setting. 2) 
Communication across space, but at the same time, which can be direct communication via a 
virtual media such as conference calls, web conferences etc. 3) Communication neither in 
time nor space, which can define written communication in reports, emails etc.    
 
  Face-to-face communication means. Proximity is often mentioned as an influential factor, as 
close physical location can stimulate flow of knowledge (Gulati, 1998; Rosenfeld,	   1997; 
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Hoegl and Proserpio, 2004) as both formal and informal interactions can occur (Porter, 1998; 
Gulati, 1998). The co-location of partners also stimulates a common frame of reference and 
belief system, which is stimulating to information processing (Song éy al- 2005; Grant 1996; 
Berchicci and Tucci 2010).  
Continuous co-location of users and producers is not applicable in product testing, as the 
product is to be tested in natural business settings. However, in the planning of product 
testing producers can arrange for face-to-face meetings with users, which can occur at the 
firm, on site or at professional settings such as technological or industry related conferences. 
Through these face-to-face meetings the dynamics of co-location can be applied, as users can 
communicate testing experiences directly with the producer. Thereby both formal feed back 
and more informal measures can be transferred, which leads to the following hypothesis: 
 
H2A: If collaborating partners have the means to communication directly with each other 
both in time and space (Face to Face), this will have a positive effect on users knowledge 
sharing ability with producers. 
 
  Communication direct across space. Collaboration across distance is increasing with 
globalization and it becomes more relevant to also explore communication, which may occur 
across space (Baker 2002, Powell ét al., 2004, Bathelt and Turi, 2011). Previous literature is 
inconsistent in consequences of communication in global settings, where actors communicate 
via virtual media. Some studies emphasize the social relations generated by being co-located, 
which is challenged when actors are dispersed over distance (Hoegl and Proserpio, 2004). 
Other streams of literature point to the opportunities created by technological development, 
and therefore the possibilities of generating social connection via virtual media (Bartlet and 
Turi, 2011; Hoegl ét al., 2007; Schmidt, Montoya-Weiss and Massey, 2001). It is here 
emphasized that virtual media can generate opportunities for partners to communicated 
directly and therefore give feedback and agree on a common understanding concerning a 
certain issue, which compensate for the lack of co-location (Baker, 2002; Crampton, 2002). 
This study builds on this perspective emphasizing feed back processes in knowledge sharing 
and therefore the opportunity to communicate directly at the same time, but across space, and 
hypothesize:  
 
H2B: If collaborating partners have the means to communication directly with each other in 
time (direct across space), this will have a positive effect on knowledge sharing ability. 
 
  Written communication. In line with the previous two hypotheses, which argue for a positive 
effect of actors to be able to communicate either directly in time and space, or directly in 
time, this study predicts that written communication is challenging to knowledge sharing 
ability. When controlling for face-to-face, and virtual communication, we predict a negative 
effect of written communication means, and hypothesize: 
 
H2C: If collaborating partners have the means to communication neither in time or space 
(written), this will have a negative effect on knowledge sharing ability. 
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Figure 2. Hypotheses (research model) 
 
 
Research method 
Pharmaceutical product development is an industry, which is highly dependent on their 
performance during product testing. Potential new products undergo extensive testing phases 
following strict clinical trials, which are conducted by medical sites such as private clinics, 
health centers, hospitals, and academic medical centers. During these trials pharmaceutical 
producers collaborate with users, whom have the direct access to patients, as well as 
physician’s expertise in the therapeutic area (Getz and Zuckerman 2010). Companies develop 
trial protocols and manuals for product use, which sites apply in the clinical trials. Feedback 
from the sites on safety and efficiency of the new products are then reported back to the 
company and entails the application to the regulatory authorities for gaining approval of the 
new product to the market (Hathaway ét al. 2009). Physicians are thereby integrated in the 
development of new products before market launch, thus presenting an example of how users 
in some industries are a central player in the down-stream processes.  
As the medical sites are the main decisive partners on the market, by being responsible for 
prescribing drugs and guiding patients (end-users) on product usage, the medical sites are in 
this paper referred to as the professional users.  
 
Data collection 
To test the hypotheses a study among medical sites participating in clinical trials in 
pharmaceutical drug development processes were carried out. These site representatives are 
difficult to locate and identify, as there are no public listings of these sites. A contact list to 
clinical sites was developed through previous studies including industry respondents. Here 
Pharmaceutical partners were asked to supply contact information to their site stakeholders, 
which amounted to a list of more than 1500 functioning clinical sites. This unique list of 
otherwise enclosed information was applied in this study and from this a questionnaire 
developed. 395 site representatives responded to the questionnaire, which therefore supply a 
substantial sample size, and a satisfactory response rate of approximately 25 %.  
In order to obtain a rich measure for users ability to share knowledge with the producer, the 
question were divided in to 11 sub-questions covering 11 topic areas, as identical 4 point 
Likert scales. The aim of this study is to explore if some topics are more difficult to generate 
knowledge about and share between user and producer. Three topic areas are explored. 1) 
Issues related directly to the product’s functionality, which in the case of Pharmaceutical 
product development is topics related to the safety and efficacy of the new drug. 2) Issues 
concerning related services, which in drug development refer to the management of the drug 
in the clinical practice. Service issues concerning the application of the new drug in practice, 
Users Knowledge 
 Sharing Ability 
(Rasch scale measure) 
Communication Mean, face-to-face 
Communication Mean, direct across space 
Communication Mean, written 
+ 
+ 
- 
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and related to a medical clinic or hospitals administration issues. 3) Usability issues, which in 
drug development refer to the end-users responds to design related topics.  
In the development of the topic items relevant for the pharmaceutical testing process, the 
study guidelines, which is a manual to the users during the testing process, was studied. The 
study guidelines focus primarily on the product functionality, as the prime goal is testing for 
safety and efficacy in order to acquire regulatory approval. However, as this study wants to 
explore users knowledge generation and sharing beyond product functionality other topic 
areas was explored. Here the clinical practice guidelines were studied, as these guidelines are 
applied after a drug has been approved. Clinical practice guidelines are a written document 
applied in the practical application of a drug by the clinical personal at hospitals or other 
health centers. The post-market launch perspective was applied to understand which topic 
areas were relevant for the users in practice. These guidelines include issues of product 
related service, which is relevant for the application of the drug in practice, as well as 
usability related issues related to the end-user (patient) comfort. The topic items were listed 
randomly in the actual questionnaire as listed in table 1.   
 
Table 1. Topic items regarding the drug development testing divided by product, 
service or usage topic items 
Item No. Question content Issue item 
1 Drug side effects Product 
2 Administration of the new drug (e.g. taken with meal, taken in the evening, on empty stomach etc.) Usage 
3 Concomitant drug interactions Product 
4 Delivery form (tablet, capsule, injection etc.) Usage  
5 Dosage of new drug Product 
6 Cost effectiveness of new drug Service  
7 Patient access to the drug Usage  
8 Risk/benefit from intervention Product 
9 Clinical skills necessary for successful drug administration Service   
10 Workforce required for drug administration Service  
11 Patients and professionals reaction to branded name Service  
 
 
Method  
The papers method is twofold. To answer hypothesis 1 a Rasch scale model is applied in 
order to make a diverse scale of users ability to share knowledge with the producer. Hereafter 
the Rasch scale measure, which will be a result of the Rasch analysis of hypothesis one, will 
be applied as the dependent variable in a regression analysis. 
 
Rasch scale modeling 
To study hypothesis 1 and therefore how users ability to share knowledge with the producer 
may be differentiated by topic area, Rasch scale modeling is applied, (Rasch, 1980; Bond and 
Fox, 2001) which is part of the item response theory, IRT (Singh, 2004; de Jong ét al., 2008). 
Instead of focusing on dependent and independent variables, item response theory focus on 
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measuring related items and their positioning on a scale (Singh 2004). A Rasch scale model 
is applied to evaluate the relationship between items measured by probability statistics 
modeling (Singh 2004; Rasch 1980).  
The loadings of the respondent’s answers to the 11 item areas, measured on a 4 point likert 
scale, are entered into the Rasch model. The Rasch score then defines the ability of the site 
respondent to contribute with information on the same scale as the item difficulties. The scale 
output is thereby an illustration of the item/person relationship. The person measure on the 
scale illustrates which sites are able to provide which information to the producer. The item 
measure defines an order of the items by assigning difficulty values to the 11 items defined in 
table 1. The scale thereby assigns a relative measure on a common continuum defining how 
difficult a certain item topic is to share relative to the other item topics. The measure can 
thereby support an analysis of users ability to share knowledge by assigning different 
difficulties of sharing knowledge from user to producer.  
The interest point of this paper is the relationship between the items, but the scale of persons 
is related and contributes with indications of model fit (Bond and Fox 2001). If the item-
person scale does not correspond, it implies that the chosen items does not describe the issue 
area in question, which in this case is person’s ability to share knowledge. Item fit statistics 
thereby supply information concerning the fit between the Rasch scale model and the 
observed data. Such infit/outfit measures can be identified in the analysis and will be 
elaborated on in the result section.  
 
Measures    
To validate the result of the Rasch scale model and therefore also hypothesis 1 a regression 
model is developed. Further, a regression model is applied to explore hypothesis 2A-2C, and 
therefore the effect of communication mean on users ability to share knowledge with the 
producer.   
Dependent variable. Besides presenting a scale, which makes it possible to relate topics 
items directly to each other, the Rasch method also produce a single measure representing the 
scale. The Rasch measure can be defined as the likelihood of a certain item topic to score 
high in the likert scale answered by the respondents (Bond and Fox, 2001). The measure 
therefore integrates a loading of the item topics in an overall measure and represents a more 
differentiated measure, than if a mean of all item areas was developed. This measure can be 
entered into a regression model, to further validate the scale results, and test the effect of 
communication mean on the scale outcome. The Rasch scale measure produced from a 
scaling of users ability to share knowledge with the producer is thereby applied as the 
dependent variable in a regression analysis.  
 
Independent variables. To test the effect of communication mean on users ability to share 
knowledge with the producer, three groupings of communication means are applied:  
1) Communication mean – Face-to-face (F2F). F2F communication between user and 
producer includes meetings where the actors have an opportunity to meet directly with each 
other and discuss development related issues. Respondents were asked to indicate on a three 
point likert scale how often they have; Sponsor visits at site (face-to-face communication). 
Here the sponsor (pharmaceutical company) visit the site and speak directly with the site 
representatives. Or Off site meetings and conferences, which included industry specific 
conferences or related forums where site- and pharmaceutical representatives meet.  
2) Communication mean – direct across space. Communication across space is here defined 
as meetings where user and producer can communicate directly with each other in time, but 
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not present at the same location. The respondents were here asked to indicate on the same 
three point likert scale how often they have; Telephone conversations/conferences calls etc., 
or Web-based meetings. In the case of clinical trials, medical sites are often in multiple global 
locations, and the sponsor company therefore collaborates with partners across the world. 
Direct across space communication is therefore defined as telephone conferences and web-
based meetings, where actors are not at the same location, but have the opportunity to 
communicated directly and therefore discuss, reflect and give direct feed-back.  
3) Communication mean – Written. Written communication is defined as a more classical 
communication mean, where user and producer communicate via written means. 
Respondents were here asked to indicate how often they communicate by; Email exchange or 
General written communication. In clinical trials much documentation about the results of the 
trial is documented in reports, which is then transferred from site to the firm. 
 
  Controls. Two types of control variables are applied in the model: 1) Variables related to the 
user characteristics, 2) Variables related to the collaboration process between user and 
producer:  
1A) Job role of site representative is applied as a control measure, which characterizes the 
users role, as site representatives in clinical trials can be doctors, nurses or administrative 
staff. We categorize the job role in two groupings: Medical users and supporting staff. This 
dichotomous categorization control for the type of knowledge and resources the user 
represents, as the doctors will have most insights into the specific product area.  
1B) Experience of users is also applied as a control variable, as this may influence the 
medical staffs´ ability to share their knowledge from clinical trial participation. Users 
experience is measured in years of clinical trial participation and therefore as a numerical 
measure.  
2A) Personal relations. It is a well-known factor in the industry that the same sites may be 
applied continuously. This is both due to the site and individual doctors role in the market, 
which is especially important if they are considered as a key opinion leader. Or it may be due 
to the personal relations established over time, which therefore make the sponsor-site relation 
important to both partners. In studying the effect of communication mean on knowledge 
sharing ability, we therefore also control for the personal relationships between site and 
sponsor.  
2B) Post trial meetings. Drug development resembles the stage gate model to a high degree 
(Cooper, 2001), as each clinical trials result in a go/no go decision, and therefore end of a 
trial and collaboration with a medical site. However, producers may interact post trial 
termination, and we control for post trial interaction between user and producer, and therefore 
for non-targeted variance in the post trial phases.  
 
 
Results  
To address hypothesis 1 a scale-modeling tool is applied in order to explore the difficulty of 
sharing knowledge between user and producer by topic area. The 11 topic items (Table 1), 
which are categorized as topic items related to product functionality (safety and efficacy), 
related services or usability issues are entered into a Rasch scale model. The results of the 
Rasch analysis is in the following presented in two output measures; 1) Fit statistics, which 
illustrate the fit of the scale and therefore if the 11 topic items cover the knowledge gained 
and shared between user and producer. 2) Item difficulty, which scale the difficulty of 
generating and sharing knowledge concerning the 11 topic items between user and producer.  
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Fit statistics 
Fit statistics are computed in the Rasch analysis and supply information concerning the fit of 
the data in relation to the Rasch output map. The mean square values should have an 
expected value around 1, but values will exist above and below this. If the MNSQ infit values 
are significantly lower than 1 some dependencies are present in the data, and if higher than 1 
then some noise should be considered in the model (Linacre 2010). Further, MNSQ outfit 
level significantly lower than 1 also imply dependency in the data, while an MNSQ outfit 
level significantly above 1 indicate that there is some unexpected outliers in the chosen 
variables.  
 
Table 2. Fit statistics, Rasch analysis (Winstep output) 
Item Description Issue Difficulty MNSQ 
No.  item  Infit Outfit 
6 Cost effectiveness of new drug Service 1.57 1.14 1.15 
11 
Patients and professionals reaction to branded 
name Service 1.26 1.19 1.22 
7 Patients access to the drug Usability .80 .90 .87 
10 Workforce required for drug administration Service .41 .77 .75 
4 Delivery form (tablet, capsule, injection etc.) Usability .07 1.03 1.09 
2 
Administration of the new drug (e.g. taken 
with meal, taken in the evening, on empty 
stomach etc.) Usability -.18 .91 .96 
9 
Clinical skills necessary for successful drug 
administration Service -.27 .81 .78 
5 Dosage of new drug Product -.44 .98 .96 
8 Risk/benefit from intervention Product -.59 .93 .87 
3 Concomitant drug interactions Product -.74 .90 .90 
1 Drug side effects Product -1.89 1.29 1.32 
Difficulty: degree of users ability to share with producer reflected in the specific item. 
 
 
A rule of thumb is a level within +/- .2 (.80/1.2) (Bond and Fox 2001). Item number 1 
therefore shows some sign of both noise and outliers, and item 10 show tendency to 
dependency in the data. The MNSQ fit statistics for item 1 and 10 is however not 
substantially different than 1, and is both critical issues within the empirical area studied – 
clinical trials - and is therefore kept in the model. This should however be considered if 
specific conclusions about item number 1 or 10 is drawn isolated. As mentioned in the 
introduction we primarily observe the items as part of a grouping – clinical practice issues or 
product management issues – and as so the items with borderline fit statistics are kept in the 
model.  
In item statistics the measurement method of the individual items can support reliability of 
the model, if the measurement items are alike. However, this can create some validity issues, 
which is better supported if the item measurements are different from each other (Singh 
2004). In this study´ Rasch analysis the item measurements are alike and therefore the model 
reliable. However, the tradeoff can be an under-identifying power of the model, as the scale 
may not cover some issues. This can be observed in the model by the person measurements in 
the left side of the scale, which should be within the range of the item measures on the rights 
side of the model. If person measurements and item measurements are not in the lower part of 
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the model floor effects can be observed, and correspondent ceiling effects in the top of the 
model.  
An over-representation of person items above the high difficult measure (Item 6, difficulty 
1.57) can be observed, which suggest that the model is slightly under-represented. This is a 
limitation to the model, and should be considered in future research. This model indicates a 
clear pattern concerning the included item topics, but also point to the need of further 
development and inclusion of more item topics in future studies.  
 
Item difficulty  
Besides item 1 and item 10, which reflect some fit challenges to the model, the other nine 
items are well represented within the fit limits in the Rasch analysis. This indicates, that users 
generate and share relevant knowledge concerning product functionality, related services and 
usability issues by participating in test phases in NPD. The model illustrate that managerial 
issues are relevant to pursue in utilizing user capabilities. Users actually obtain knowledge 
concerning the late stage development process, which are not in direct line with their 
professional profile. The model reveal that the managerial issues are more difficult to 
transfer, which both can be due to the profile of the users, and the existing processes of 
perceiving and utilizing users resources. 
Figure 1 illustrates the Rasch map generated by the Rasch scale-modeling program Winstep 
(Linacre 2010). On the left side of the model the respondents are represented in relation to 
their answers to the 11 items. On the right side of the continuum the items are outlined in 
relation to each other.  
 
 
Figure 3. Item-person map, Winstep output 
	   12	  
Overall there is a tendency for issues related to product functionality to be easier to generate 
and share than issues on related services and usability of the product. In the bottom of the 
scale shown in figure 2 items 1, 3, 8 and 5 can be observed. These 4 items all relates directly 
to the products functionality, and therefore the safety and efficacy of the new drug: drug side 
effects, drug interactions, risk/benefit from intervention and dosage of new drug. The bottom 
of the scale indicates, that the issues related to product functionality are easiest to transfer in 
relation to the other items measured on this scale.  
The four item issues related to product functionality are therefore easier to generate 
knowledge about and transfer to the producer. The other 7 item issues, which are more 
difficult to transfer, all relate to either service or usability issues. In the end of the continuum, 
and therefore representing the most difficult issues to generate knowledge about and transfer 
to the producer, is item 6 and 11. Item 6 - cost effectiveness and item 11 – reaction to 
branded name, are both related service issues, which are highly relevant for the final market 
launch. Though, these issues are not crucial to the regulatory approval, and therefore not 
required to tests for in the clinical phases.  These issues are therefore not a standard measure 
in the study guidelines, and also not in the clinical practice guidelines, but central issues in 
the application of the drug at hospitals and clinics.   
Also in the most difficult end of the scale item 7 - Patients access to the drug (service) and 
item 10 - workforce required for drug administration (usability) can be observed. These 
issues are also not requirements according to the regulatory approval, and therefore related to 
safety and efficacy. But they are important to clinical practice and can therefore be applied in 
clinical practice guidelines.  
In the middle of the continuum item 2, 4 and 9 can be observed. These three issue areas 
(Administration of drug, Delivery form and clinical skills necessary) does not directly apply 
to the product functionality and is therefore not prime topics in the study guidelines. 
However, these issues are all highly relevant to clinical practice after a drug have been 
approved, as is therefore mentioned in the medical sites clinical practice guidelines applied in 
the application of the final drugs.  
The Rasch scale outcome illustrates a pattern, which relates to the conceptual categorization 
of topics in product, service and usability. Hypothesis 1 stating that issue items related 
directly to product functionality are not as difficult to generate and transfer between user and 
producer, as service related and usability issues, can be confirmed. The scale analysis 
illustrates that service and usability topics are more difficult to generate and transfer by the 
users, than issue related to product functionality.  
To test this result further, the Rasch scale measure is applied in a regression analysis where 
the effect of communication mean are explored.     
 
Knowledge sharing ability and communication mean 
As global activities increase, so does the communication across large distances. This have 
brought by many technological opportunities in which partners can communicate directly 
with each other even though not in the same locations, such as tele- and web conferences 
(Baker 2002, Bathelt and Turi 2011). This issue can be defined as a differentiation among 
TIME and SPACE, as partners may communicate at the same time, but across geographical 
space. We follow this division of communication mean in this study, as clinical trials have 
experienced a great globalization in the last years, and therefore often have multiple sites on 
many global locations integrated in one trial. We therefore make three variables in relation to 
communication mean in order to test this issue further: 1) Direct communication, face-to-
face. 2) Direct communication, direct across space. 3) Written communication.  
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Table 3. Results for regression analysis of the effect of communication mean on users 
ability to share knowledge with the producer. 
  Model 1 Model 2 
Predictors  B t-value B t-value 
  Control variables       
Personal relations   .93** 2.44 .79** 2.07 
Post trial efforts   .76* 2.68 .48* 1.67 
Job role   .36 1.59 .66*** 2.93 
User experience   -.00 -.11 .00 .11 
  Independent variables      
Communication mean  Face to face   .49* 1.90 
 Direct across space   .97*** 3.52 
 Written   -.03 -.08 
 
   
R2  .047 .119 
Adjusted R2  .036 .101 
df   333 330 
*=p < 0.1,  **=p < 0.05, ***=p < 0.01, n = 337 
 
The regression analysis reveals that written communication does not have a significant effect 
on users ability to share knowledge. However, both face-to-face communication (Unst. coef. 
B: .49, t: 1.9) and communication across space (Unst. coef. B: .97, t: 3.52) have a positive 
effect, and we can thereby confirm hypothesis 2a and 2B. Notable is, that even though face to 
face communication means have a significant effect on the scale of knowledge sharing ability 
of users, the effect of direct communication across space is higher. Communication across 
space have a high t value, which supports studies of knowledge sharing across distance, and 
expands on previous studies claiming that proximity promotes social relations, which 
generate knowledge sharing. Global connections are possible in today’s collaborative 
connections in new product development, as long as partners have the opportunity to 
communicate direct in time, and therefore as things occur. Face-to-face communication 
among global partners has the disadvantage, that issues are then discussed on a later point in 
time, when global partners have a chance to meet. This is also the case in drug development, 
as face-to-face interaction occurs, when Pharmaceutical companies visit the sites, or they 
have meetings off site, or at conferences. This can be useful and this papers result also show 
an effect of this mean of communication. But in a global collaboration framework, the 
communication means across space, but at the same time, and therefore via virtual means of 
communication, give partners the opportunity to give direct feed-back, and users to articulate 
ongoing reflections.  
 
 
Discussion 
This papers extended perspective on testing optimization builds on the perspectives on beta-
testing by Dolan and Matthews (1993), and adds to traditional perspectives of product testing 
in NPD literature (Cooper 2001, Shaw 1988) where product functionality and marketing 
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measures is the prime goal. The results of the analysis show, that it is relevant to differentiate 
between product functionality, and then related services (which also include marketing 
measures) and then usability patterns. Users gain information about more than direct 
functionality issues, but also other measures, which is relevant for the producer in the further 
development, adjustment and launch of the new product. In the testing processes of the 
Pharmaceutical industry the processes is primarily build on formal information processing 
structures, where users are to gather information related to product functionality, which is 
required by regulatory authority before market approval. However, this study reveals that 
users gain information, which extends beyond the required safety and efficacy measures. 
These issues on related services and usability patterns are though more difficult for the user 
to share with the producer. The industry is therefore not optimally utilizing users expertise 
gained from intense integration in late stage development phases. This may be due to 
pressure on the time-consuming and costly trial phases (DiMasi and Grabowski 2007), which 
therefore are being optimized for regulatory purposes. This may however compromise 
valuable knowledge input related to the application of the product, design optimization and in 
general issues related to the testing process it self.   
The results of the effect of communication mean on knowledge sharing ability further 
emphasis the importance of the relation between user and producer. No effects of written 
communication means on knowledge sharing ability was found, which is interesting as much 
information concerning clinical trials is transferred in written reports, templates etc. ready for 
regulatory review. The positive effect of both face-to-face and virtual direct communication 
illustrates the importance of being able to communicate directly with each other during 
product testing. In such settings informal information processing can occur, and therefore the 
sharing of knowledge, which go beyond product functionality issues. It was here interesting 
to observe, that previous arguments for the importance of co-location (Song ét al- 2005; 
Grant 1996; Berchicci and Tucci 2010) was challenged by and increased effect of 
communication means, where global actors could communicate directly when things occur. 
Communication means where actors can supply feed back and reflections during the process 
have a strong effect of knowledge sharing ability. In organization product testing in high-tech 
product development the means to which users can supply and discuss they experiences with 
the product in use is therefore important. Direct communication between producer and user 
can stimulate the output generated by producers in product testing.  
These results are interesting in relation to the development of the testing processes in the 
Pharmaceutical industry. The expenses of clinical trials are continuingly increasing in the 
pharmaceutical industry even though more products are not entering the market (Kaitin 
2010). There is therefore a common understanding in the industry that the extensive time-
consuming and costly development process needs to be more effective. These motives have 
made pharmaceutical companies outsource previous in-house competences, such as site 
selection and data management, which are both closely connected to the relationship to trials, 
to a broker agent (Howells 2006; Hargadon and Sutton 1997; Bessant and Rush 1995; Gould 
and Fernandez 1998) The use of outsourcing to a broker agent in the late stage of drug 
development now often included CROs managing the direct relations to trial sites as 
companies outsource clinical trial processes in a full service partnership (FSP) (Getz and 
Zuckerman 2008; Bodenheimer 2000). It has been recognized that the integration of a CRO 
may generate savings on cost and time  (Getz 2007; Kaitin 2010) as these organizations are 
specialized in the down-stream task of clinical trial management. There is however limited 
research focusing on the challenges the integration of a third part agent may course to the 
utilization of the users capabilities in down stream product development. The direct tie 
between sponsors and clinical sites may be jeopardized as the task of trial management are 
not perceived as a core competence and therefore moved to a third party agent. The flow of 
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unique knowledge obtained in the clinical trial phases may therefore be compromised in the 
new structures of drug development, which should be further explored in future studies.  
 
 
Conclusions  
This study has revealed that knowledge concerning product related services and usability 
patterns are more difficult to share between user and producer, than direct product 
functionality issues. Further, the analysis shows a significant effect of communication face-
to-face and direct across locations on users knowledge sharing ability. Notable was that 
communication means across space but direct in time had a higher effect than face-to-face 
interactions. This indicates that the means to communicate directly and thereby the ability to 
reflect and obtain feedback when things occur is important to knowledge sharing between 
user and producer.  
 
 
Managerial implications  
Late stage network partners in the Pharmaceutical industry are primarily perceived as 
providers of concrete and pre-defined information concerning the clinical trials. However, the 
primary down-stream network partner, the medical sites, is highly qualified knowledge 
workers whom posses in-depth knowledge about the product and the related services and 
usability issues through their extensive integration in the down stream process. Users well-
defined role in down-stream development may prevent the producer from tapping knowledge, 
which go beyond the issues and tasks medical users are expected to perform. The results 
indicate that pre-defined user roles may limit industry to optimally utilize the potential 
knowledge from users. Therefore, when highly skilled users are integrated in high-tech 
product testing processes, managers should consider the competences gained beyond the 
expected outcome of product functionality testing. An optimization of the utilization of users 
knowledge gained in product testing could thereby strengthen the product functionality, 
design and market launch, and potentially create spin-off products. Incorporating systems to 
utilize user input on a broader scale is therefore recommended in the planning of product 
testing in late stage development. In the design of the testing process managers should also 
consider the importance of direct interaction with the user, and here especially directly in 
time with the many global sites. Establishing good communication means where users can 
communicate with the producers as things occur can stimulate knowledge transfer concerning 
both product functionality and related services and usability issues.        
 
 
Limitations and future research directions 
Applying the Rasch scale model have supplied this study with several opportunities in 
relation to the research question, but also represents some limitations. A challenge to Rasch 
scale modeling is the construct and application of item measures. The individual items 
measured in relation to persons (data ID measures) needs to be constructed with continuity, 
and also representing the overall topic area to a satisfactory degree (Bond and Fox, 2001). 
This can create some challenges in the reliability of the continuum spread of the Rasch scale 
output. The data collection in this study has aimed at a high level of continuity in the items, 
by generating parallel questions and answer options, which have meet the limitation of 
reliability of scale items in the Rasch method. However, the spread of the items in relation to 
the person IDs represent some under-identification in the model. This is considered in the 
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conclusions of the study, which is kept on the level of differentiating between the two defined 
groupings; Managerial issues, and clinical issues. We suggest, that future research focus on 
expanding the scale of items, which can generate conclusions about specific management 
issues, individually and in relation to each other. It is relevant to explore further, which 
specific management issue areas users generate knowledge about, and how this knowledge is 
utilized by producers and further integrated in the production processes.  
The Rasch scale model has proven to be beneficial in exploring issues in management 
research, and we therefore suggest that this approach is further developed for innovation 
management studies.  
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